Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Healthtrust
US Department of Justice
Merck
McKesson
McKinsey
Farmers Insurance
Cerilliant
Teva
Federal Trade Commission

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022402

« Back to Dashboard

NDA 022402 describes CODEINE SULFATE, which is a drug marketed by West-ward Pharms Int and Lannett Holdings Inc and is included in three NDAs. It is available from three suppliers. Additional details are available on the CODEINE SULFATE profile page.

The generic ingredient in CODEINE SULFATE is codeine sulfate. There are nineteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the codeine sulfate profile page.
Summary for 022402
Tradename:CODEINE SULFATE
Applicant:West-ward Pharms Int
Ingredient:codeine sulfate
Patents:0
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 022402
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 022402
Suppliers and Packaging for NDA: 022402
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CODEINE SULFATE codeine sulfate TABLET;ORAL 022402 NDA West-Ward Pharmaceuticals Corp. 0054-0243 0054-0243-24 4 BLISTER PACK in 1 BOX, UNIT-DOSE (0054-0243-24) > 25 TABLET in 1 BLISTER PACK
CODEINE SULFATE codeine sulfate TABLET;ORAL 022402 NDA West-Ward Pharmaceuticals Corp. 0054-0244 0054-0244-25 100 TABLET in 1 BOTTLE (0054-0244-25)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength15MG
Approval Date:Jul 16, 2009TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength30MG
Approval Date:Jul 16, 2009TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength60MG
Approval Date:Jul 16, 2009TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
QuintilesIMS
Cerilliant
McKesson
Queensland Health
Citi
AstraZeneca
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot